686 related articles for article (PubMed ID: 33708205)
21. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].
Zhou LL; Ye SG; Li P; Tang XC; Liang AB
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526
[No Abstract] [Full Text] [Related]
22. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
23. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
24. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
25. An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.
Pereira R; Bergantim R
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732213
[TBL] [Abstract][Full Text] [Related]
26. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
Zhou D; Zhu X; Xiao Y
Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
[TBL] [Abstract][Full Text] [Related]
27. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy: An emergency medicine focused review.
Long B; Yoo MJ; Brady WJ; Holian A; Sudhir A; Gottlieb M
Am J Emerg Med; 2021 Dec; 50():369-375. PubMed ID: 34461398
[TBL] [Abstract][Full Text] [Related]
29. Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma.
Dong R; Wang Y; Sun X; Lin Y; Luo Y; Xing C; Sun L; Zhang S; Yu K; Jiang S; Chen Y
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):911-916. PubMed ID: 37777383
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
[TBL] [Abstract][Full Text] [Related]
31. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
32. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
Banerjee R; Fakhri B; Shah N
Leuk Lymphoma; 2021 Nov; 62(11):2600-2611. PubMed ID: 34151714
[TBL] [Abstract][Full Text] [Related]
33. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.
Yan W; Liu Z; Liu J; Xia Y; Hu K; Yu J
Biomed Res Int; 2020; 2020():4241864. PubMed ID: 33062678
[TBL] [Abstract][Full Text] [Related]
34. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
[TBL] [Abstract][Full Text] [Related]
35. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma.
Brammer JE; Braunstein Z; Katapadi A; Porter K; Biersmith M; Guha A; Vasu S; Yildiz VO; Smith SA; Buck B; Haddad D; Gumina R; William BM; Penza S; Saad A; Denlinger N; Vallakati A; Baliga R; Benza R; Binkley P; Wei L; Mocarski M; Devine SM; Jaglowski S; Addison D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429331
[TBL] [Abstract][Full Text] [Related]
36. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
37. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Juluri KR; Wu QV; Voutsinas J; Hou J; Hirayama AV; Mullane E; Miles N; Maloney DG; Turtle CJ; Bar M; Gauthier J
Blood Adv; 2022 Apr; 6(7):2055-2068. PubMed ID: 34666344
[TBL] [Abstract][Full Text] [Related]
38. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
Fleischer LC; Spencer HT; Raikar SS
J Hematol Oncol; 2019 Dec; 12(1):141. PubMed ID: 31884955
[TBL] [Abstract][Full Text] [Related]
39. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
Walton ZE; Frigault MJ; Maus MV
Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
[TBL] [Abstract][Full Text] [Related]
40. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
Liu Y; Deng B; Hu B; Zhang W; Zhu Q; Liu Y; Wang S; Zhang P; Yang Y; Yang J; Zheng Q; Yu X; Gao Z; Zhou C; Han W; Yang J; Jin L; Tong C; Chang AH; Zhang Y
Blood Adv; 2022 Feb; 6(3):717-730. PubMed ID: 34521107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]